Raleigh, NC (September 18, 2018) — Contego Medical announced today that [...]

Raleigh, NC, March 7, 2018 -- Contego Medical, LLC has announced the beginning of enrollment in the PERFORMANCE I Trial, a clinical trial designed to evaluate the safety and feasibility of the Neuroguard IEPâ 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection. The Neuroguard IEP System is designed to treat clinically significant carotid artery stenosis, further expanding Contego Medical’s portfolio of neurovascular solutions.

Raleigh, NC, (September 12, 2017) -- Contego Medical, LLC announced today the initiation of the ENTRAP Study evaluating usage of its Vanguard IEP® Peripheral Balloon Angioplasty System with Integrated Embolic Protection in patients receiving peripheral angioplasty. First cases with the device were performed by Ralf Langhoff, M.D. at Sankt Gertrauden Krankenhaus in Berlin, Germany, with the first enrolled patient treated by Koen Deloose, M.D. at AZ Sint Blasius in Dendermonde, Belgium. The Vanguard IEP System received CE mark in April 2017.

Raleigh, NC, (April 27, 1017) — Contego Medical, LLC announced today that it has received CE Marking of its Vanguard IEPä Peripheral Balloon Angioplasty System with Integrated Embolic Protection. The Company intends to launch the Vanguard IEP System in Europe to endovascular specialists performing lower limb angioplasty procedures.

Raleigh, NC (July 20, 2016) — Contego Medical, LLC announced today that it has completed enrollment in the Paladin^® Carotid PostDilation Balloon System Registry in Europe. The registry involved 5 centers with 100 total patients, and represents the first prospective clinical evaluation of a new class of device that provides Integrated Embolic Protection™ (IEP) technology for interventional treatment of carotid stenosis.

Data presented at the Leipzig Interventional Course (LINC) demonstrates breakthrough treatment for Carotid Artery Disease
Raleigh, NC (January 26, 2016) — Contego Medical, an innovator in developing next generation treatments for coronary and peripheral artery disease, today presented positive post-­market registry data for the Paladin® Carotid Post-­Dilation Balloon with Integrated Embolic Protection™ (IEP) Technology at LINC 2016, in Leipzig, Germany. The presentation included compelling results from a diffusion-­weighted MRI (DW-­MRI) sub-­study that showed improved patient outcomes with the Paladin System.